title: Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
abstract: Hyperuricemia is a known cardiovascular risk factor. The angiotensin II receptor blocker (ARB) losartan is known to decrease serum uric acid (UA) level. A recent in vitro study demonstrated a strong interaction between irbesartan and UA transporters that exceeded that of losartan. The purpose of the present study was to evaluate the hypouricemic effect of irbesartan in a clinical setting. A total of 40 high-risk hypertensive outpatients with coronary artery disease, cerebrovascular disease and/or diabetes complications who were taking ARBs other than irbesartan and losartan were enrolled in this study. After a 4-week control period, the patients' prescribed ARBs were exchanged for an equivalent dose of irbesartan. We assessed blood pressure, heart rate, serum UA level, parameters of lipid and glucose metabolism, cardiac and renal function and inflammatory and oxidative stress markers in blood samples taken immediately before the initiation of irbesartan treatment and again after 12 weeks of treatment. All 40 recruited patients were followed (31 men and 9 women, mean age: 68 years) without any dropouts. During the 12 weeks of irbesartan treatment, no significant changes in blood pressure, heart rate, parameters of lipid or glucose metabolism or other biomarkers of cardiac function, renal function, or inflammation were observed. However, UA level (5.9±1.6 to 5.5±1.6 mg ml(-1), P=0.028) and the oxidative stress marker derivative reactive oxygen metabolites (dROMs) (354±83 to 310±65 U.CARR, P<0.001) were significantly lower at 12 weeks of treatment compared with before treatment. These results suggest that irbesartan has beneficial effects on hyperuricemia and oxidative stress.
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Chida
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Itaru
authors.initials: I
authors.lastname: Hisauchi
authors.affiliation: Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Toyoda
authors.affiliation: Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
authors.forename: Migaku
authors.initials: M
authors.lastname: Kikuchi
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Komatsu
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Hori
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Shiro
authors.initials: S
authors.lastname: Nakahara
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Sakai
authors.affiliation: Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
authors.forename: Teruo
authors.initials: T
authors.lastname: Inoue
authors.affiliation: Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Taguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
chemical_list: D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D014527:Uric Acid; D000077405:Irbesartan